Humacyte ($HUMA) $9M Investor Settlement

Humacyte and three executives agreed to a proposed $9 million settlement resolving claims that investors were misled concerning alleged product safety, facility, and liquidity issues at the company.

Outline:

Humacyte investors accused the company and its executives of making materially false or misleading statements about important risks affecting the business. The allegations were organized around product safety, facility, and liquidity issues that plaintiffs claim inflated Humacyte’s securities prices. Humacyte agreed to resolve the litigation for $9 million.

Timeline:

• March 1, 2024: Plaintiffs identified this date as the first in a series of corrective disclosures that allegedly revealed information previously concealed from Humacyte investors.

• August 12, 2024: Humacyte securities declined following a disclosure that plaintiffs tied to the alleged Product Safety Fraud; the Court later allowed claims associated with this decline to proceed.

• October 17, 2024: Plaintiffs identified another corrective disclosure associated with allegations concerning Humacyte’s facilities and other previously undisclosed issues.

• November 18, 2024: The initial securities class action was filed against Humacyte and its executives.

• November 2, 2026: The parties executed the formal settlement agreement providing for a $9 million cash settlement.

Background:

Humacyte investors alleged that the company and several executives made materially false or misleading statements and omissions concerning significant risks affecting Humacyte’s business. The amended complaint grouped those allegations into three categories: Product Safety Fraud, Facility Fraud, and Liquidity Fraud.

According to plaintiffs, these alleged misrepresentations caused Humacyte securities to trade at artificially inflated prices. Plaintiffs identified a series of later disclosures between March 2024 and March 2025 that they claim gradually revealed information that had not previously been fully disclosed to investors.

The Court later distinguished between the three theories. It allowed the Product Safety Fraud theory to proceed at the pleading stage, finding that the plaintiffs had sufficiently alleged those claims to survive dismissal, while dismissing the Facility Fraud and Liquidity Fraud theories without prejudice.

The settlement’s allocation methodology identifies the August 12, 2024 and March 25, 2025 stock-price declines as corresponding to the claims that survived the motion to dismiss. Other declines, including those associated with disclosures in March, August, September, October, and November 2024 and March 2025, correspond to claims that were dismissed without prejudice.

The defendants deny making materially false or misleading statements, deny violating federal securities laws, and maintain that they acted in good faith. After exchanging discovery, obtaining information from the FDA through a Freedom of Information Act request, and participating in mediation, the parties agreed to resolve the securities claims for $9 million.

What Can Investors Expect Now?

Humacyte and three executives agreed to a proposed $9 million settlement resolving claims that investors were misled concerning alleged product safety, facility, and liquidity issues at the company.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.